Open Access Open Access  Restricted Access Subscription Access

An Indispensable Parameters of Hepatitis C Include Patho Physiology, Diagnosis, Differential Diagnosis, Treatment, Prognosis and Complications

Srinivas G., Ramanjaneyulu D. V., Muralinath E., Guruprasad M., Sravani Pragna K., Manjari P., Sony Sharlet E., T. Nikhil, V. Yaswanth Sai, D. Kusuma Latha, Ch. Ramya Sudha, K. Sridevi, D. Gokul Shiva Balaji

Abstract


58 million people worldwide are afflicted by the hepatitis C virus (HCV), a serious public health issue. Between 1990 and 2005, the global seropositive rate for anti-HCV antibodies is thought to have increased from 2.3% to 2.8%. When an acute infection occurs, the majority of individuals (80% to 85%) are unable to eradicate the virus and develop a chronic illness. Chronic infections can cause cirrhosis, portal hypertension, hepatocellular cancer, and hepatic decompensation with encephalopathy. Since extremely powerful direct-acting antivirals (DAAs) were introduced in 2011, the therapy landscape has changed significantly. This exercise describes the pathophysiology, assessment, and treatment of hepatitis C and emphasizes the importance of the interprofessional team in treating afflicted patients.


Full Text:

PDF

References


Mashiba, T., Joko, K., Kurosaki, M., Ochi, H., Hasebe, C., Akahane, T., Sohda, T., Tsuji, K., Mitsuda, A., Kimura, H., Narita, R., Ogawa, C., Furuta, K., Shigeno, M., Okushin, H., Ito, H., Kusakabe, A., Satou, T., Kawanami, C., Nakata, R., ... Izumi, N. (2019). Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group. Hepatology Research, 49(10), 1114–1120. https://doi.org/10.1111/hepr.13334

Morales-Arraez, D., Alonso-Larruga, A., Diaz-Flores, F., García Dopico, J. A., de Vera, A., Quintero, E., & Hernández-Guerra, M. (2019). Predictive factors for not undergoing RNA testing in patients found to have hepatitis C serology and impact of an automatic alert. Journal of Viral Hepatitis, 26(9), 1117–1123. https://doi.org/10.1111/jvh.13119

Galati, G., Muley, M., Viganò, M., Iavarone, M., Vitale, A., Dell'Unto, C., Lai, Q., Cabibbo, G., Sacco, R., Villa, E., & Trevisani, F. (2019). Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: Literature review and risk analysis. Expert Opinion on Drug Safety, 18(7), 603–610. https://doi.org/10.1080/14740338.2019.1620355

Kamimura, K., Sakamaki, A., Kamimura, H., Setsu, T., Yokoo, T., Takamura, M., & Terai, S. (2019). Considerations of elderly factors to manage the complication of liver cirrhosis in elderly patients. World Journal of Gastroenterology, 25(15), 1817–1827. https://doi.org/10.3748/wjg.v25.i15.1817

Parigi, T. L., Torres, M. C. P., & Aghemo, A. (2019). Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure. Clinical and Molecular Hepatology, 25(4), 360–365. https://doi.org/10.3350/cmh.2019.0033

Mukhtar, N. A., Ness, E. M., Jhaveri, M., Fix, O. K., Hart, M., Dale, C., Pratt, C., & Kowdley, K. V. (2019). Epidemiologic features of a large hepatitis C cohort evaluated in a major health system in the western United States. Annals of Hepatology, 18(2), 360–365. https://doi.org/10.1016/j.aohep.2018.11.007

Soi, V., Daifi, C., Yee, J., & Adams, E. (2019). Pathophysiology and treatment of hepatitis B and C infections in patients with end-stage renal disease. Advances in Chronic Kidney Disease, 26(1), 41–50. https://doi.org/10.1053/j.ackd.2018.09.002

Simoncini, G. M., & Koren, D. E. (2019). Hepatitis C update and expanding the role of primary care. Journal of the American Board of Family Medicine, 32(3), 428–430. https://doi.org/10.3122/jabfm.2019.03.180267

Maticic, M., Zorman, J. V., Gregorcic, S., Schatz, E., & Lazarus, J. V. (2019). Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: A cross-sectional survey of 34 European countries. Harm Reduction Journal, 16(1), 32. https://doi.org/10.1186/s12954-019-0291-6

Lam, J. O., Hurley, L. B., Chamberland, S., Champsi, J. H., Gittleman, L. C., Korn, D. G., Lai, J. B., Quesenberry, C. P., Ready, J., Saxena, V., Seo, S. I., Witt, D. J., Silverberg, M. J., & Marcus, J. L. (2019). Hepatitis C treatment uptake and response among human

immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system. International Journal of STD & AIDS, 30(7), 689–695. https://doi.org/10.1177/0956462418820772


Refbacks

  • There are currently no refbacks.